Overseas & overseers

FRAMINGHAM (02/27/2004) - University of Cambridge spinoff Paradigm Therapeutics Ltd.'s latest venture opened last month in Biopolis, a new biomedical research and development facility in Singapore. Joining the company from GlaxoSmithKline PLC, Ian Gray will lead Paradigm Therapeutics Singapore as head of research. Back in the U.S., Paradigm recently named Mark Carlton CEO and Edwin Moses non-executive chairman.

Join the newsletter!


Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.

More about GlaxoSmithKline

Show Comments